News Releases

Date Title and Summary Additional Formats
Toggle Summary Increased Defense-Related Funding of AVI BioPharma Approved
$11 Million Allocated for Development of Therapeutics for Ebola, Marburg and Dengue Viruses, and for Countermeasures for Anthrax and Ricin Toxins   PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 4, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that President Bush has approved the final
View HTML
Toggle Summary AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus
NEUGENE Antisense Compound Was Well-Tolerated and Exhibited Favorable Pharmacokinetic Parameters   PORTLAND, Ore., Jan 10, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced favorable safety and pharmacokinetic results from the first phase of its clinical trial for
View HTML
Toggle Summary AVI BioPharma's NEUGENE Shows Success Against Deadly Ebola Virus
Results Published in Online Journal Public Library of Science (PLoS) Pathogens   PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 13, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced publication of significant research carried out in collaboration with the U.S.
View HTML
Toggle Summary AVI BioPharma Reports Confirmation of Efficacy against Influenza Strains
NEUGENE Antisense Efficacy against Influenza Strains, Including Avian Influenza, to Lead to IND Filing with the FDA   PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today announced confirmation from three independent laboratories of NEUGENE(R) antisense
View HTML
Toggle Summary AVI BioPharma Announces Hepatitis C Virus License Agreement with Chiron
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that it has entered into an agreement with Chiron Corp. granting AVI a nonexclusive license to Chiron's patents and patent applications for the research, development and commercialization of antisense
View HTML
Toggle Summary Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
PORTLAND, Ore.--(BUSINESS WIRE)--Feb. 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that successful results from a new application of its proprietary NEUGENE(R) antisense technology, called ESPRIT (Exon Skipping Pre-RNA Interference Technology), were reported in the February issue of
View HTML
Toggle Summary AVI BioPharma Announces 2005 Fourth Quarter and Year End Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--March 1, 2006--AVI BioPharma Inc. (Nasdaq:AVII) today announced that the Company will hold a conference call to discuss its 2005 fourth quarter and year end financial results on Wednesday, March 8, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery
Additional Efficacy Results Published in the Journal Antimicrobial Agents and Chemotherapy   PORTLAND, Ore.--(BUSINESS WIRE)--March 7, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that the February issue of Nature Reviews Drug Discovery (Nature Reviews 5:103-106, 2006) chose to
View HTML
Toggle Summary AVI BioPharma Announces 2005 Fourth Quarter and Full Year Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--March 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and 12 months ended December 31, 2005. For the fourth quarter of 2005, AVI reported a net loss of $4.6 million, or $0.10 per share, compared with a net loss of $5.0
View HTML
Toggle Summary AVI BioPharma Incorporated 2005 Fourth Quarter and Year–End Financial Results Conference Call Transcript
Moderator: Denis Burger March 8, 2006 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2005 Fourth Quarter and Year–End Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we’ll hold a Q&A session.
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.